Myoinositol ameliorates high-fat diet and streptozotocin-induced diabetes in rats through promoting insulin receptor signaling

Biomedicine and Pharmacotherapy

Volumn 88, Issue , 2017, Pages 1098-1113

  Antony, Poovathumkal James ^a   Gandhi, Gopalsamy Rajiv ^a,b   Stalin, Antony ^a   Balakrishna, Kedike ^a   Toppo, Erenius ^a   Sivasankaran, Kuppusamy ^a   Ignacimuthu, Savarimuthu ^a,c   Al Dhabi, Naif Abdullah ^c  

^a LOYOLA COLLEGE   (India)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adipose; Biochemical; Diabetes; Histology; Myoinositol; cell

Indexed keywords

CREATININE; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INSULIN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; TYLOXAPOL; UREA; GLUCOSE BLOOD LEVEL; LIPID; MACROGOL DERIVATIVE; MESSENGER RNA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL FUNCTION; CONTROLLED STUDY; DIABETES CONTROL; DRUG STRUCTURE; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MIMOSA PUDICA; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIET RESTRICTION; DRINKING BEHAVIOR; DRUG EFFECTS; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIAS; INSULIN RESISTANCE; KIDNEY; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DRINKING BEHAVIOR; FASTING; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; INOSITOL; INSULIN; INSULIN RESISTANCE; KIDNEY; LIPIDS; LIVER; MALE; MOLECULAR DOCKING SIMULATION; POLYETHYLENE GLYCOLS; RATS, WISTAR; RECEPTOR, INSULIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 85011995343     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.01.170     Document Type: Article

References (39)

1. [1] Dewanjee, S., Das, A.K., Sahu, R., Gangopadhyay, M., Antidiabetic activity of Diospyros peregrina fruit: effect on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2 diabetes. Food Chem. Toxicol. 47 (2009), 2679–2685.
2. [2] Gandhi, G.R., Vanlalhruaia, P., Stalin, A., Irudayaraj, S.S., Ignacimuthu, S., Paulraj, M.G., Polyphenols-rich Cyamopsis tetragonoloba (L.) Taub. beans show hypoglycemic and β-cells protective effects in type 2 diabetic rats. Food Chem. Toxicol. 66 (2014), 358–365.
3. [3] Sharma, B., Balomajumder, C., Roy, P., Hypoglycemic and hypolipidemic effects of flavonoid rich extract from Eugenia jambolana seeds on streptozotocin induced diabetic rats. Food Chem. Toxicol. 46 (2008), 2376–2383.
4. [4] Lim, K.H., Han, J.H., Lee, J.Y., Park, Y.S., Cho, Y.S., Kang, K.D., Yuk, W.J., Hwang, K.Y., Seong, S.I., Kim, B., Kwon, J., Kang, C.W., Kim, J.H., Assessment of antidiabetogenic potential of fermented soybean extracts in streptozotocin-induced diabetic rat. Food Chem. Toxicol. 50 (2012), 3941–3948.
5. [5] Ahmad, H., Sehgal, S., Mishra, A., Gupta, R., Mimosa pudica L. (Laajvanti): an overview. Phcog. Rev. 6 (2012), 115–124.
6. [6] Joseph, B., George, J., Mohan, J., Pharmacology and traditional uses of Mimosa pudica. Int. J. Pharm. Sci. Drug Res. 5 (2013), 41–44.
7. [7] Sridharan, S., Vaidyanathan, M., Venkatesh, K., Nayagam, A.A.J., GC–MS study and phytochemical profiling of Mimosa pudica Linn. J. Pharm. Res. 4 (2011), 741–742.
8. [8] Croze, M.L., Soulage, C.O., Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95 (2013), 1811–1827.
9. [9] Ortmeyer, H.K., Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys. Obes. Res. 4 (1996), 569–575.
10. [10] Lee, K.M., Overview of drug product development. Curr. Protoc. Pharmacol. 7 (2001), 1–10.
11. [11] Cerdan, S., Hansen, C.A., Johanson, R., Inubushi, T., Williamson, J.R., Nuclear magnetic resonance spectroscopic analysis of myo-inositol phosphates including inositol 1,3,4,5-tetrakisphosphate. J. Biol. Chem. 261 (1986), 14676–14680.
12. [12] Oliveira, H.C., Santos, M.P.D., Grigulo, R., Lima, L.L., Martins, D.T., Lima, J.C., Stoppiglia, L.F., Lopes, C.F., Kawashita, N.H., Antidiabetic activity of Vatairea macrocarpa extract in rats. J. Ethnopharmacol. 115 (2008), 515–519.
13. [13] Levine, S., Saltzman, A., A procedure for inducing sustained hyperlipidemia in rats by administration of a surfactant. J. Pharmacol. Toxicol. Methods 55 (2007), 224–226.
14. [14] Trinder, P., Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann. Clin. Biochem. 6 (1969), 24–27.
15. [15] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
16. [16] Reitman, S., Frankel, S.A., Colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 28 (1957), 56–63.
17. [17] Kind, P.R.N., King, E.J., Estimation of plasma phosphatases by determination of hydrolyzed phenol with amino-antipyrine. J. Clin. Pathol. 7 (1954), 322–330.
18. [18] Wybenga, D.R., Di-Giorgio, J., Pileggi, V.J., Manual and automated methods for urea nitrogen measurement in whole serum. Clin. Chem. 17 (1971), 891–895.
19. [19] Slot, C., Plasma creatinine determination. A new and specific Jaffe reaction method. Scand. J. Clin. Lab. Invest. 17 (1965), 381–387.
20. [20] Gandhi, G.R., Ignacimuthu, S., Paulraj, M.G., Hypoglycemic and β-cells regenerative effects of Aegle marmelos (L.) Corr. bark extract in streptozotocin-induced diabetic rats. Food Chem. Toxicol. 50 (2012), 1667–1674.
21. [21] Gandhi, G.R., Ignacimuthu, S., Paulraj, M.G., Solanum torvum Swartz. fruit containing phenolic compounds shows antidiabetic and antioxidant effects in streptozotocin induced diabetic rats. Food. Chem. Toxicol. 49 (2011), 2725–2733.
22. [22] McDonald, J.W., Pilgram, T.K., Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology 34 (1999), 439–446.
23. [23] Lee, Y.S., Cha, B.Y., Saito, K., Yamakawa, H., Choi, S.S., Yamaguchi, K., Yonezawa, T., Teruya, T., Nagai, K., Woo, J.T., Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem. Pharmacol. 79 (2010), 1674–1683.
24. [24] Muthusamy, V.S., Saravanababu, C., Ramanathan, M., Raja, R.B., Sudhagar, S., Anand, S., Lakshmi, B.S., Inhibition of protein tyrosine phosphatase 1 B and regulation of insulin signaling markers by caffeoyl derivatives of chicory (Cichoriumintybus) salad leaves. Brit. J. Nutr. 104 (2010), 813–823.
25. [25] Gandhi, G.R., Stalin, A., Balakrishna, K., Ignacimuthu, S., Paulraj, M.G., Vishal, R., Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3 K/p-Akt signaling pathway by embelin in type 2 diabetic rats. BBA-Gen. Subj. 1830 (2013), 2243–2255.
26. [26] Sanner, M.F., Python: a programming language for software integration and development. J. Mol. Graph. Model 17 (1999), 57–61.
27. [27] Boden, G., Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 45 (1996), 3–10.
28. [28] Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., Lazar, M.A., The hormone resistin links obesity to diabetes. Nature 409 (2001), 307–312.
29. [29] Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52 (2005), 313–320.
30. [30] Krol, E., Krejpcio, Z., Evaluation of anti-diabetic potential of chromium (III) propionate complex in high-fat diet fed and STZ injected rats. Food Chem. Toxicol. 49 (2011), 3217–3223.
31. [31] Veerapur, V.P., Prabhakar, K.R., Thippeswamy, B.S., Bansal, P., Srinivasan, K.K., Unnikrishnan, M.K., Antidiabetic effect of Ficus racemosa Linn. stem bark in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats: a mechanistic study. Food Chem. 132 (2012), 186–193.
32. [32] Zhang, L., Yang, J., Chen, X.Q., Zan, K., Wen, X.D., Chen, H., Wang, Q., Lai, M.X., Antidiabetic and antioxidant effects of extracts from Potentilla discolor Bunge on diabetic rats induced by high fat diet and streptozotocin. J. Ethnopharmacol. 132 (2010), 518–524.
33. [33] Zheng, T., Shu, G., Yang, Z., Mo, S., Zhao, Y., Mei, Z., Antidiabetic effect of total saponins from Entada phaseoloides (L.) Merr. in type 2 diabetic rats. J. Ethnopharmacol. 139 (2012), 814–821.
34. [34] Friedman, M., Bayer, S.O., The mechanism underlying hypocholesterolemia induced by Triton WR 1339. Am. J. Physiol. 190 (1957), 439–445.
35. [35] Pintaudi, B., Vieste, G.D., Bonomo, M., The effectiveness of myoinositol and D-chiroinositol treatment in type 2 diabetes. Int. J. Endocrinol. 2016 (2016), 1–5.
36. [36] Rej, R., Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin. Chem. 24 (1978), 1971–1979.
37. [37] Sunil, C., Duraipandiyan, V., Agastian, P., Ignacimuthu, S., Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats. Food Chem. Toxicol. 50 (2012), 4356–4363.
38. [38] Navarro, M.C., Montilla, M.P., Martin, A., Jimenez, J., Utrilla, M.P., Free radicals scavenger and antihepatotoxic activity of Rosmarinus tomentosus. Plant Med. 59 (1993), 312–314.
39. [39] Bethesda, M.D., Renal Data System, U.S., Annual Data Report: Atlas of End Stage Renal Disease in the United States., 2001, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases.